CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 83 enrolled
Drug / intervention
Amicus Red Cell Exchange in SCD patientsdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02372877
NCT02372877N/ACompleted
CompareCT.gov

Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients

Fenwal, Inc.·interventional·Posted Feb 26, 2015·Updated Jul 29, 2022

In Brief

A clinical study evaluating Amicus Red Cell Exchange in SCD patients for Sickle Cell Anemia. Completed, enrolled 83 participants across 6 sites.

Detailed Summary

The purpose of this study is to evaluate the performance of the AMICUS Red Blood Cell Exchange (RBCx) System (Exchange and Depletion/Exchange procedures) in patients with sickle cell disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Anemia
CountriesUnited States
CollaboratorsVersiti Blood Health, Children's Hospital of Philadelphia, Barbara Ann Karmanos Cancer Institute, University of Texas, Washington University School of Medicine, Phoenix Children's Hospital

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 26, 2015
Enrollment StartMay 1, 2015
Primary CompletionDec 7, 2017
Study CompletionJan 19, 2018
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 11.3 years ago

Interventions

Amicus Red Cell Exchange in SCD patientsdevice

Each patient will be treated with one RBCx procedure using the AMICUS RBCx System